Insulet Appoints Timothy J. Scannell to Board of Directors

Insulet Appoints Timothy J. Scannell to Board of Directors 
Seasoned Senior Medical Device Executive to Join Insulet Board 
BEDFORD, MA -- (Marketwired) -- 08/15/14 --  Insulet Corporation
(NASDAQ: PODD), the leader in tubeless insulin pump technology with
its OmniPod(R) Insulin Management System, today announced the
appointment of Timothy J. Scannell to the Company's board of
directors. A seasoned senior medical device executive, Mr. Scannell
currently serves as Group President, MedSurg & Neurotechnology at
Stryker Corporation. 
Mr. Scannell brings more than twenty years of accelerated success at
Stryker to the Insulet board. Mr. Scannell's general management
responsibilities at Stryker date back to 2001, and since 2008 he has
served as group president overseeing multiple global businesses
including Neurotechnology, Endoscopy, Medical, Sustainability
Solutions, Instruments and CMF. These divisions are responsible for
U.S. sales, global R&D, global marketing, business development and
elements of regulatory affairs/quality assurance, distribution,
service and legal. 
"Tim is a highly respected and experienced industry leader with an
exceptional track record and we are thrilled to have him join our
team," said Duane DeSisto, President and Chief Executive Officer of
Insulet. "Tim's strategic, organizational and operational skills
along with his history of consistently driving market leading sales
growth and operating income growth for his businesses will be
tremendous assets to the company." 
Mr. Scannell served as General Manager and President of Stryker Spine
from 2003 to 2008 and led all functions of the business. Mr. Scannell
was in charge of Stryker's Biotech division as Vice President and
General Manager from 2001 to 2003.  
Mr. Scannell began his career with Stryker in 1990. During eleven
years with Stryker's Endoscopy division, he served in various sales
and marketing leadership roles and progressed to the position of
Executive Vice President, overseeing sales, marketing and operations.
Mr. Scannell earned his Bachelor's and his Master's degree in
Business Administration from the University of Notre Dame. 
About Insulet Corporation 
 Insulet Corporation (NASDAQ: PODD) is an
innovative medical device company dedicated to making the lives o
people with diabetes easier. Through its OmniPod Insulin Management
System, Insulet seeks to expand the use of insulin pump therapy among
people with insulin-dependent diabetes. The OmniPod is a
revolutionary and easy-to-use tubeless insulin pump that features
just two parts and fully-automated cannula insertion. Insulet's
subsidiary, Neighborhood Diabetes, is a leading distributor for
diabetes products and supplies, delivered through a high touch
customer service model. To read inspiring stories of people with
diabetes living their lives to the fullest with OmniPod, visit our
customer blog, Suite D: Founded in 2000,
Insulet Corporation is based in Bedford, Mass. For more information,
please visit: 
Insulet Corporation
877-PODD-IR1 (877-763-3471) 
Press spacebar to pause and continue. Press esc to stop.